BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 29, 2011
View Archived Issues
AZD-4547 shows preclinical potential to treat solid tumors
Read More
TTAC-0001 displays antitumor efficacy in various models
Read More
Second-generation tumor metabolism inhibitor PENAO shows promise in vitro and in vivo
Read More
Antibody-drug conjugate BAY-94-9343 is active against mesothelin-expressing tumors
Read More
Novel inhibitors of human neutrophil elastase prepared
Read More
Nano Terra licenses three new products to Kadmon Pharma
Read More
Genetic markers of prostate cancer mortality identified in castration-resistant disease
Read More
AY-4 inhibits tumor growth in model of head and neck cancer
Read More
TransTech patents new compounds for Alzheimer's disease
Read More
Kuros Biosurgery regains rights to several products from Baxter
Read More
Vical reports promising phase I data on Vaxfectin-adjuvanted H1N1 pandemic flu vaccine
Read More
Merck & Co. presents new melanin-concentrating hormone MCH1 receptor antagonists
Read More
Eli Lilly and Medtronic form drug-device collaboration for Parkinson's disease
Read More
FDA approves additional indication for Lamictal XR
Read More
Novel PET tracers presented by University of Zagreb
Read More
Columbia Labs submits NDA to FDA for Prochieve to reduce risk of preterm birth
Read More
New antiprotozoal compounds reported
Read More
Dyax and Five Prime join to identify therapeutic antibodies against multiple targets
Read More
Primary endpoints met in phase II Vyvans trial in schizophrenia
Read More
Capstone Therapeutics reports final data from phase IIa AZX-100 trial
Read More
Adherex Technologies enrolls first patient in phase II eniluracil trial
Read More
OncoMed receives FDA clearance to advance anticancer candidate OMP-18R5 into phase I
Read More
FDA approves Zytiga in combination with prednisone for metastatic CRPC
Read More
Unigene completes enrollment in phase II study of oral parathyroid hormone for osteoporosis
Read More
Mirapex LA tablet approved in Japan for Parkinson's disease
Read More
Karo Bio and Alkem Laboratories enter collaboration and license agreement for eprotirome
Read More
